Urgent warning issued for Ozempic after GLP-1 drugs linked to suicide
Monday, December 1, 2025 – New precautions added for GLP-1 drugs as reports of mood changes and contraceptive concerns emerge in Australia.
Cardiovascular benefits of GLP-1 drugs independent of weight loss
Saturday, November 22, 2025 – Revising our earlier interpretation of SELECT trial data in light of new analyses The post Cardiovascular benefits of GLP-1 drugs independent of weight loss appeared first on Peter Attia.
Itching at the GLP-1 site of injection
Tuesday, November 11, 2025 – Some people will get itching at the site of injection of the GLP-1 drugs. This is not common but is irritating. There are some things you can do to lessen the severity of the reaction.
Trump Cuts Prices on Ozempic and Wegovy in Deal With GLP-1 Weight Loss Drug Makers
Thursday, November 6, 2025 – President Trump’s plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular GLP-1 weight loss drugs.
EASO Framework for Pharmacological Obesity Treatment – Sick Fat vs. Fat Mass
Friday, October 31, 2025 – A framework published by the European Association for the Study of Obesity (EASO) that addresses the pharmacological treatment of obesity and its complications. This framework proposes a new treatment algorithm that goes beyond solely focusing on weight loss,…
Surgery beats Ozempic for long-term health, Cleveland Clinic finds
Saturday, October 18, 2025 – Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.
💪 The HIV and Weight Loss Drugs Connection – GLP-1 Agonists in HIV Management
Sunday, August 3, 2025 – The provided source explores the increasing use of GLP-1 receptor agonists like semaglutide and liraglutide in individuals with HIV. It highlights that these medications are beneficial for addressing obesity and metabolic syndrome, common issues exacerbated by antiretroviral therapy, by…
💲 Medicare’s Weight Loss Drug Experiment: Costs & Coverage
Sunday, August 3, 2025 – A Washington Post article talks about the Trump administration experiment to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs like Ozempic, potentially benefiting millions of Americans struggling with obesity. This initiative, a reversal of a previous…
Where is GLP-1 is produced and where in the body does it act?
Friday, August 1, 2025 – The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal L-cells and the brainstem’s nucleus of the solitary tract (NTS).…
⚖️ GLP-1s: Integrating Diet and Activity for Optimal Outcomes
Thursday, July 31, 2025 – This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and managing both insufficient and excessive weight loss, emphasizing individualized approaches.…